Biotech Companies Navigate Trump's New Tariffs on Imported Materials

Smaller biotech firms are facing significant challenges as they work to obtain exemptions from Trump's new import tariffs on critical materials and components. These tariffs could increase production costs for pharmaceutical and medical device manufacturers, potentially affecting drug development timelines and accessibility. The biotech industry is actively lobbying for relief measures to protect research and development operations. For patients, increased costs could translate to higher medication prices and delayed access to new treatments in development. Understanding these policy changes is important as they may impact healthcare costs and innovation in Puerto Rico and across the United States.